疑似遗传性肺纤维化中TERT和TERC基因突变的患病率与特征
该研究回顾性分析了2007-2014年间237例肺纤维化患者(153例家族性肺纤维化,84例仅端粒综合征特征)的TERT/TERC基因检测结果,发现16.8%携带疾病相关变异,且与年轻、红细胞大细胞症和低血小板计数相关,携带者无移植生存期更短。
要点
- TERT/TERC疾病相关变异在疑似遗传性肺纤维化中患病率为16.8%。
- 年轻(40-60岁)、红细胞大细胞症和低血小板计数与变异存在相关。
- 携带TERT/TERC变异者无移植生存期显著低于未携带者(4.2年 vs 7.2年,p=0.046)。
核心结论
- TERT/TERC疾病相关变异与特定临床和生物学特征相关,并降低无移植生存期。
研究设计与样本
- 回顾性分析2007-2014年237例肺纤维化患者(153例家族性肺纤维化,84例仅有端粒综合征特征)的TERT/TERC基因检测结果。
主要发现
- 40例(16.8%)检出TERT/TERC疾病相关变异,包括5例非特发性间质性肺炎。
- 家族性肺纤维化与仅有端粒综合征特征的患者间变异患病率无显著差异(18.2% vs 16.4%)。
- 年轻、红细胞大细胞症和低血小板计数与变异存在相关;40-60岁患者变异概率增加。
- 携带变异者无移植生存期低于未携带者(4.2年 vs 7.2年,p=0.046)。
关键数值与推荐
- TERT/TERC疾病相关变异总患病率为16.8%(40/237)。
- 家族性肺纤维化组患病率18.2%,仅有端粒综合征特征组16.4%。
- 无移植生存期:携带变异者4.2年,未携带者7.2年(p=0.046)。
临床怎么用
- 对疑似遗传性肺纤维化患者应进行TERT/TERC基因检测。
- 年轻、红细胞大细胞症或低血小板计数可提示TERT/TERC变异可能。
- 检出TERT/TERC变异者预后较差,需更密切随访和移植评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Telomerase reverse transcriptase (TERT) or telomerase RNA (TERC) gene mutation is a major monogenic cause of pulmonary fibrosis. Sequencing of TERT/TERC genes is proposed to patients with familial pulmonary fibrosis. Little is known about the possible predictors of this mutation and its impact on prognosis.We retrospectively analysed all the genetic diagnoses made between 2007-2014 in patients with pulmonary fibrosis. We evaluated the prevalence of TERT/TERC disease-associated variant (DAV), factors associated with a DAV, and the impact of the DAV on survival.237 patients with pulmonary fibrosis (153 with familial pulmonary fibrosis, 84 with telomere syndrome features without familial pulmonary fibrosis) were tested for TERT/TERC DAV. DAV was diagnosed in 40 patients (16.8%), including five with non-idiopathic interstitial pneumonia. Prevalence of TERT/TERC DAV did not significantly differ between patients with familial pulmonary fibrosis or with only telomere syndrome features (18.2% versus 16.4%). Young age, red blood cell macrocytosis, and low platelet count were associated with the presence of DAV; the probability of DAV was increased for patients 40-60 years. Transplant-free survival was lower with than without TERT/TERC DAV (4.2 versus 7.2 years; p=0.046).TERT/TERC DAV were associated with specific clinical and biological features and reduced transplant-free survival.
引用
- Borie R, Tabèze L, Thabut G, et al. Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. Eur Respir J. 2016. PMID: 27836952. doi:10.1183/13993003.02115-2015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。